key: cord-0426368-f60z8jo2
authors: Suthar, Mehul S.; Arunachalam, Prabhu S.; Hu, Mengyun; Reis, Noah; Trisal, Meera; Raeber, Olivia; Chinthrajah, Sharon; Davis-Gardner, Meredith E.; Manning, Kelly; Mudvari, Prakriti; Boritz, Eli; Godbole, Sucheta; Henry, Amy R.; Douek, Daniel C.; Halfmann, Peter; Kawaoka, Yoshihiro; Zarnitsyna, Veronika I.; Nadeau, Kari; Pulendran, Bali
title: Durability of immune responses to the BNT162b2 mRNA vaccine
date: 2021-09-30
journal: bioRxiv
DOI: 10.1101/2021.09.30.462488
sha: 93ff517d9da7347b26096dae0fe7e32dea338cf0
doc_id: 426368
cord_uid: f60z8jo2

The development of the highly efficacious mRNA vaccines in less than a year since the emergence of SARS-CoV-2 represents a landmark in vaccinology. However, reports of waning vaccine efficacy, coupled with the emergence of variants of concern that are resistant to antibody neutralization, have raised concerns about the potential lack of durability of immunity to vaccination. We recently reported findings from a comprehensive analysis of innate and adaptive immune responses in 56 healthy volunteers who received two doses of the BNT162b2 vaccination. Here, we analyzed antibody responses to the homologous Wu strain as well as several variants of concern, including the emerging Mu (B.1.621) variant, and T cell responses in a subset of these volunteers at six months (day 210 post-primary vaccination) after the second dose. Our data demonstrate a substantial waning of antibody responses and T cell immunity to SARS-CoV-2 and its variants, at 6 months following the second immunization with the BNT162b2 vaccine. Notably, a significant proportion of vaccinees have neutralizing titers below the detection limit, and suggest a 3rd booster immunization might be warranted to enhance the antibody titers and T cell responses.

significant proportion of vaccinees have neutralizing titers below the detection limit, and suggest a 3 rd booster immunization might be warranted to enhance the antibody titers and T cell responses.

The development of the highly efficacious mRNA vaccines in less than a year since the emergence of SARS-CoV-2 represents a landmark in vaccinology. The efficacy of the Pfizer-BioNTech (BNT162b2) and

Moderna (mRNA1273) vaccines were 95% (95% confidence limits 90.3% to 97.6%) 1 and 94.1% (95% confidence limits 89.3% to 96.8%) 2 , respectively, for a median of 2 months following the second dose.

However, reports of waning vaccine efficacy [3] [4] [5] , coupled with the emergence of variants of concern that are resistant to antibody neutralization, have raised concerns about the potential lack of durability of immunity to vaccination. While the durability of antibody responses to the mRNA1273 vaccine has been reported recently 5 , there is a lack of data on the durability of immune responses induced by the BNT162b2. We recently reported findings from a comprehensive analysis of innate and adaptive immune responses in 56 healthy volunteers who received two doses of the BNT162b2 vaccination 6 . Here, we analyzed antibody responses to the homologous Wu strain as well as several variants of concern, including the emerging Mu Of the 56 volunteers, we were able to collect blood samples from 46 participants on day 210. Anti-Spike binding IgG response measured in all 46 participants declined 7.3-fold between days 42 and 210, with two individuals showing a response below the limit of detection (Fig. 1a) . The decline in response was 6.3-fold in female participants and 9.1-fold in male participants, but the difference in responses was not statistically significant (Fig. 1a) . Consistent with this, the authentic live virus neutralization antibody titers against the homologous USA-WA1/2020 strain were 7-fold lower at 6 months relative to the titers at 3 weeks (Fig. 1b) . The decline in response was 6.6-and 7.4-folds in female and male participants, respectively (Fig. 1b) . Of note, we performed this assay in all 46 volunteers in Vero-E6 cells to compare with the data we reported recently 6 and all the previous studies where we used this assay 5,7-9 . The durability of neutralizing titers against the homologous strain was comparable to that of the responses in mRNA1273 vaccinees 5, 10 . To examine this methodically, we calculated decay rates of binding and neutralizing antibody responses using an exponential decay model, which assumes a steady decay rate over time. The estimated half-lives of binding and neutralizing antibody responses were 58 (95% Cl: 53.5 to 62.5) and 56 (95% Cl: 51 to 62) days, respectively (Fig. 1c) . We also employed the power law model, which assumes a decreased decay rate over time. While the estimated decay rate was 81 days using this model, a corrected Bayesian information criterion used to compare models suggested that the exponential decay model provided the best fit. In comparison, the half-life of live-virus neutralizing antibody response to mRNA1273 vaccination was 68 days (95% Cl: 61 to 75) as described in a previous study 10 . In contrast, the half-life of live-neutralizing antibody response was estimated as 150 days in COVID-19 infected individuals 11 . In the case of other inactivated vaccines such as the diphtheria or tetanus vaccines, the decay rates of the antibody response have been calculated to be in the order of a year or so 12 . In contrast, analysis of decay rates of immune responses induced by live viral vaccines such as those against measles, rubella, vaccinia, mumps, and VZV, performed using the exponential decay modes, indicate essentially no decay in the antibody response, highlighting the remarkable durability of the response stimulated by these vaccines 12 .

Next, we measured T cell responses in 12 individuals to measure the durability of memory T cells.

Spike-specific CD4 T cells expressing IFN-g and TNF were significantly downregulated on day 210 compared to day 28; however, the IL-2 + CD4 T cell response did not differ significantly (Fig. 2a) . The frequency of spike-specific circulating Tfh-like (follicular T helper) cells expressing IL-21 and CD154, critical for their role in the germinal center formation and generation of durable antibody responses, were also significantly downregulated by day 210 (Fig. 2b) . However, even at the peak, the frequency was only modest compared to effector cytokines such as IFN-g and TNF 6 . Similarly, frequencies of antigen-specific CD8 T cells secreting IL-2, IFN-g, and TNF demonstrated a marked diminution and were below the detection limit in most participants (Fig. 2c) on day 210.

The emergence of several variants of concern since the development of BNT162b2 has raised concerns on the cross-neutralization potential of vaccine-induced antibody responses. To evaluate cross-neutralization, we performed an in vitro live virus Focus Reduction Neutralization Test (FRNT) 13 (Fig. 3a) . There was a significant reduction (up to 7-fold) in the titers against these variants at 6 months. At 6 months, the FRNT50 GMTs were 43 for WA1/2020 (95% CI, 21 to 77), 26 for Beta (95% CI, 15 to 41), 25 for Delta (95% CI, 15 to 35), 44 for Gamma (95% CI, 15 to 77), and 32 for Mu (95% CI, 25 to 102). Furthermore, we compared the efficiency of cross-neutralization of the variants of concern in serum at day 42 and day 210 (Fig. 3b) with previous reports suggesting this as the most difficult-to-neutralize strain owing to mutations associated with immune escape from infection-and vaccine-induced antibodies 14, 15 (Fig. 3b, left panel) . On day 210, the difference between WA1 and Beta strains was only 1.7-fold, suggesting that potent antibodies that could cross-neutralize were maintained. However, 9 of the 17 participants (53%) had a titer against the Beta variant that were below the detection limit of the assay (Fig. 3b, right panel) . On the other hand, the neutralizing antibody response to the delta variant (B.1.617.2) that became the dominant circulating strain in several countries worldwide since its first description in October 2020 was reduced 1.7-fold at both day 42 and 210-time points (Fig. 3b) . Similar to the beta variant, 47% of the volunteers had an undetectable neutralizing response to the delta variant (Fig. 3b, right panel) . Importantly, we also measured the neutralizing response against the Mu (B.1.621) variant, first reported in Colombia earlier this year, and has recently been added to the growing list of variants of concern. Of note, the response to the Mu variant was 2.3-fold lower in comparison to the WA1 strain in day 42 sera (Fig. 3b, left panel) . The magnitude of the decline was intermediate between delta and beta variants. On day 210, 53% of participants had titers below the detection limit compared to the beta variant (Fig. 3b, right panel) .

In summary, these data demonstrate a substantial waning of antibody responses and T cell immunity to SARS-CoV-2 and its variants, at 6 months following the second immunization with the BNT162b2 vaccine. Notably, a significant proportion of vaccinees have neutralizing titers below the detection limit, and suggest a 3 rd booster immunization might be warranted to enhance the antibody titers and T cell responses. Virus stock sequencing. All viral working stocks were deep sequenced. Illumina-ready libraries were generated using NEBNext Ultra II RNA Prep reagents (New England BioLabs) as previously described 18 .

Briefly, we fragmented RNA, followed by double-stranded cDNA synthesis, end repair, and adapter ligation. The ligated DNA was then barcoded and amplified by a limited cycle PCR and the barcoded Quantification and Statistical Analysis. Antibody neutralization was quantified by counting the number of foci for each sample using the Viridot program 19 . The neutralization titers were calculated as follows: 1 -(ratio of the mean number of foci in the presence of sera and foci at the highest dilution of respective sera sample). Each specimen was tested in duplicate. The FRNT-50 titers were interpolated using a 4-parameter nonlinear regression in GraphPad Prism 8.4.3. Samples that do not neutralize at the limit of detection at 50% are plotted at 15 and was used for geometric mean calculations.

T cell intracellular cytokine assay. Live frozen PBMCs were revived, counted, and resuspended at a density of 2 million live cells per ml in complete RPMI (RPMI supplemented with 10% FBS and antibiotics). The cells were rested overnight at 37°C in a CO2 incubator. The next morning, the cells were counted again, resuspended at a density of 15 million cells per ml in complete RPMI and 100 μl of cell suspension containing 1.5 million cells was added to each well of a 96-well round-bottomed tissue culture plate. Each sample was treated with two conditions, no stimulation and a peptide pool spanning the spike protein at a concentration of 1 μg ml −1 of each peptide in the presence of 1 μg ml −1 of anti-CD28 (clone CD28.2, BD Biosciences) and anti-CD49d (clone 9F10, BD Biosciences) as well as anti-CXCR3 and anti-CXCR5. The peptides were custom synthesized to 90% purity using GenScript, a commercial vendor. All 

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. medRxiv

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Heterogeneity and longevity of antibody memory to viruses and vaccines

Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

An Infectious cDNA Clone of SARS-CoV-2

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates

Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus

National Institutes of Health (NIH), by intramural funding from the National Institute of Allergy and Infectious Diseases, Emory Executive Vice President for Health Affairs Synergy Fund award, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children's Healthcare of Atlanta, the Emory-UGA Center of Excellence for Influenza Research and Surveillance

COVID-19 CURE Award; the Parker foundation (to K.C.N.); and the Crown foundation (to K.C.N.). Funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data

and decision to submit the manuscript for publication

This work was supported in part by NIH grants HIPC U19AI090023 (to B.P.), U19AI057266 (to B.P. and principal investigator R. Ahmed (Emory University)); Open Philanthropy (to B.P.); the Sean Parker Cancer Institute; the Soffer endowment (to B.P.); the Violetta Horton endowment (to B.P.); NIH P51 OD011132,